Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.7943
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
0.8100
+0.0157 (1.98%)
Pre-market: Sep 8, 2026, 7:00 AM EDT
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$648
Profits / Employee
-$1,538,408
Market Cap
10.00M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Lunai Bioworks | 29 |
| Daré Bioscience | 24 |
| Azitra | 13 |
| Ensysce Biosciences | 10 |
| Immuron | 7 |
APRE News
- 10 days ago - Aprea Therapeutics provides update on existing patent portfolio - TheFly
- 10 days ago - Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - GlobeNewsWire
- 22 days ago - Aprea Therapeutics reports Q2 EPS (7c), consensus (22c) - TheFly
- 26 days ago - Aprea Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire
- 26 days ago - Aprea Therapeutics Earnings release: Q2 2026 - Filings
- 26 days ago - Aprea Therapeutics Quarterly report: Q2 2026 - Filings
- 27 days ago - Aprea Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - GlobeNewsWire